Active vitamin D analog and SARS‐CoV‐2 IgG after BNT162b2 vaccination in patients with hemodialysis

Abstract

IntroductionVaccination is the effective strategy for coronavirus disease 2019 (COVID‐19). However, few studies have investigated the association between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) immunoglobulin (Ig)G and vitamin D.MethodsThis study aimed to investigate the association between SARS‐CoV‐2 IgG and active vitamin D analogs in hemodialysis patients. Blood samples were collected four times: before vaccination and 30, 60, and 90 days after vaccination, BNT162b2 (Pfizer©).ResultsA total of 418 patients were enrolled. The mean age was 71.1 ± 12 years. Almost two thirds of the patients were prescribed active vitamin D analogs. The distribution of SARS‐CoV‐2 IgG before vaccination was 235 (93–454) AU/mL. After multiple regression analyses, active vitamin D analog use was found to be associated with higher SARS‐CoV‐2 IgG levels from prevaccination to 90 days postvaccination.ConclusionThis study demonstrated an association between higher SARS‐CoV‐2 IgG and active vitamin D analog use in hemodialysis patients.Clinical trial registration: The study information was registered in the UMIN‐CTR (UMIN 000046906).